ワクチン接種後のブレイクスルー感染


Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
 Abu-Raddad LJ, Chemaitelly H, Butt AA; National Study Group for COVID-19 Vaccination (Correspondence)〔N Engl J Med. 2021 Jul 8;385(2):187-189〕(査読済み)


Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
 Thompson MG, Burgess JL, Naleway AL, et al. 〔N Engl J Med 2021 Jul 22;385(24):320-329〕(査読済み)


Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar (Research Letter)
 Bertollini R, Chemaitelly H, Yassine HM, et al. 〔JAMA. 2021 Jul 13;326(2):185-188〕(査読済み)


Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
 Kustin T, Harel N, Finkel U, et al. 〔Nat Med. 2021 Aug;27(8):1379-1384〕(査読済み)


BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
 Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. 〔Clin Microbiol Infect. 2021 Jul 7:S1198-743X(21)00367-0〕(査読済み)


Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples (Research Letter)
 Bates TA, Leier HC, Lyski ZL, et al.〔JAMA. 2021 Jul 21;326(9):868-9〕(査読済み)


Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
 Bergwerk M, Gonen T, Lustig Y, et al. 〔N Engl J Med. 2021 Jul 28:NEJMoa2109072〕(査読済み)


Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers (Correspondence)
 Lange B, Gerigk M, Tenenbaum T 〔N Engl J Med. 2021 Aug 18:NEJMc2108076〕(査読済み)


Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021
 Fowlkes A, Gaglani M, Groover K, et al. 〔MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1167-1169〕(査読済み)